BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10854555)

  • 1. Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma.
    Takiuchi H; Hirata I; Kawabe S; Egashira Y; Katsu K
    Oncol Rep; 2000; 7(4):841-6. PubMed ID: 10854555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum.
    Boku N; Chin K; Hosokawa K; Ohtsu A; Tajiri H; Yoshida S; Yamao T; Kondo H; Shirao K; Shimada Y; Saito D; Hasebe T; Mukai K; Seki S; Saito H; Johnston PG
    Clin Cancer Res; 1998 Jun; 4(6):1469-74. PubMed ID: 9626464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma.
    Chung YS; Yamashita Y; Inoue T; Matsuoka T; Nakata B; Onoda N; Maeda K; Sawada T; Kato Y; Shirasaka T; Sowa M
    Cancer; 1997 Jul; 80(1):1-7. PubMed ID: 9210702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
    Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients.
    Fukuda H; Takiguchi N; Koda K; Oda K; Seike K; Miyazaki M
    Cancer Invest; 2006; 24(3):235-41. PubMed ID: 16809149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of low dose administration of 5-fluorouracil and cisplatin in patients with advanced and recurrent gastric cancer.
    Kim R; Murakami S; Ohi Y; Inoue H; Yoshida K; Toge T
    Int J Oncol; 1999 Nov; 15(5):921-6. PubMed ID: 10536174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy of continuous 5-FU infusion and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas.
    Tsuji A; Morita S; Horimi T; Takasaki M; Takahashi I; Shirasaka T
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():528-34. PubMed ID: 10895205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin.
    Nagashima F; Boku N; Ohtsu A; Yoshida S; Hasebe T; Ochiai A; Sakata Y; Saito H; Miyata Y; Hyodo I; Ando M
    Jpn J Clin Oncol; 2005 Dec; 35(12):714-9. PubMed ID: 16303791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
    Kollmannsberger C; Quietzsch D; Haag C; Lingenfelser T; Schroeder M; Hartmann JT; Baronius W; Hempel V; Clemens M; Kanz L; Bokemeyer C
    Br J Cancer; 2000 Aug; 83(4):458-62. PubMed ID: 10945491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
    Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP
    J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
    Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
    Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
    Felici A; Carlini P; Ruggeri EM; Gamucci T; Pollera CF; De Marco S; Fariello AM; Moscetti L; Gelibter A; Adami E; Sperduti I; Cognetti F
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):59-64. PubMed ID: 16001173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers].
    Tsuji A; Morita S; Horimi T; Takasaki M; Takahashi I; Shirasaka T
    Gan To Kagaku Ryoho; 1999 Jun; 26(7):933-8. PubMed ID: 10396320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma.
    Uncu D; Ozdemir NY; Aksoy S; Abali H; Oksuzoglu BC; Budakoglu B; Yildiz R; Aslan N; Zengin N
    Asian Pac J Cancer Prev; 2010; 11(6):1493-7. PubMed ID: 21338186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
    Bamias A; Hill ME; Cunningham D; Norman AR; Ahmed FY; Webb A; Watson M; Hill AS; Nicolson MC; O'Brien ME; Evans TC; Nicolson V
    Cancer; 1996 May; 77(10):1978-85. PubMed ID: 8640659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer.
    Wang B; Zhang W; Hong X; Guo Y; Li J
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):213-8. PubMed ID: 18343924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequence-dependence of cisplatin and 5-fluorouracil in advanced and recurrent gastric cancer.
    Koizumi W; Kurihara M; Hasegawa K; Chonan A; Kubo Y; Maekawa R; Iwasaki R; Sasai T; Fukuyama Y; Ishikawa K; Miyoshi K; Yasutake K; Hayakawa M
    Oncol Rep; 2004 Sep; 12(3):557-61. PubMed ID: 15289837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
    J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study.
    Hofheinz RD; Hartung G; Samel S; Hochhaus A; Pichlmeier U; Post S; Hehlmann R; Queisser W
    Onkologie; 2002 Jun; 25(3):255-60. PubMed ID: 12119460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma.
    Kim YH; Shin SW; Kim BS; Kim JH; Kim JG; Mok YJ; Kim CS; Rhyu HS; Hyun JH; Kim JS
    Cancer; 1999 Jan; 85(2):295-301. PubMed ID: 10023695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.